托马斯·施尼克纳 Thomas Schinecker — 罗氏集团 CEO
FORTUNE 500 #188

托马斯·施尼克纳

Thomas Schinecker

罗氏集团 (Roche Group)

领导Switzerland大型Pharmaceuticals企业运营

广告

专业领域

医疗健康管理 生命科学

Healthcare management, life sciences

核心贡献

领导Switzerland大型Pharmaceuticals企业运营

Leading large-scale Pharmaceuticals operations in Switzerland

最新观点

  • Roche H1 2026 Investor Update · 2026-07-23 阅读原文

    2026年上半年保持强劲势头,恒定汇率下销售额增长6%,管线取得积极进展,FDA授予五项优先审评

    Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development. We reported positive phase III data for divarasib, reinforcing its potential as a best-in-class therapy in advanced lung cancer. Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews.

  • BioSpace - Roche Pipeline · 2026-07-23 阅读原文

    晚期管线项目充足,到2030年最多可能有19款药物上市,因此公司并不像部分同行那样面临追加并购的压力

    I think we're well set up for growth into the next decade. In fact, our late-stage pipeline is so full that adding something late stage, we would then have to see how to reallocate more money into these programs. Currently, Roche is pushing several medicines through the pipeline, with up to 19 potentially launching by 2030.

广告